Free Trial
The Market Does Not Wait. MarketBeat All Access Alerts for $149
Get the Alerts
Claim MarketBeat All Access Sale Promotion
OTCMKTS:FSNUY

Fresenius SE & Co. Earnings Date & Estimates

Fresenius SE & Co. logo
$12.88 +0.11 (+0.86%)
As of 10/23/2026 03:59 PM Eastern

Fresenius SE & Co. is estimated to report earnings on Wednesday, November 4, 2026, before market opens.

Upcoming Earnings Announcement

Announcement Date
Time
Before Market Opens

What Analysts Expect from Fresenius SE & Co.

Fresenius SE & Co. is expected to post earnings of $0.2156 per share on revenue of $6.51 billion. In the same quarter a year earlier Fresenius SE & Co. reported $0.23 per share on revenue of $6.29 billion. Fresenius SE & Co. last reported on August 5, 2026, posting $0.24 per share and missing the $0.25 consensus estimate. Fresenius SE & Co. has beaten the consensus EPS estimate in 3 of its last 5 quarters.

Consensus Estimates

Consensus EPS
$0.2156
Expected Revenue
$6.51 billion
Prior-Year EPS
$0.23
Prior-Year Revenue
$6.29 billion
Expected EPS Growth
-6.3%
Expected Revenue Growth
+3.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.24 (Missed by -$0.01)
Last Quarter Revenue
$6.91 billion
EPS Beat Rate
3 of last 5 quarters

Fresenius SE & Co. Earnings FAQ

Fresenius SE & Co. (OTCMKTS:FSNUY) is estimated to report earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Fresenius SE & Co. to post earnings of $0.2156 per share for the quarter.

The consensus revenue estimate for Fresenius SE & Co. is $6.51 billion for the quarter.

Fresenius SE & Co. Earnings Headlines

Fresenius : Q3 2026 Aide Memoire available
Federal Reserve’s Disturbing Plan To Control Your Money
A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.tc pixel
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services. Fresenius also operates hospitals in Germany through its Helios division, which provides inpatient and outpatient medical care through a network of acute-care and rehabilitation facilities.

Fresenius traces its origins to the Hirsch Pharmacy in Frankfurt, Germany, which was acquired by the Fresenius family in the 18th century. Over time, the business developed into an international health care company serving customers and patients across Europe, North America, Latin America, Asia and other global markets. Fresenius Medical Care, historically associated with the group’s dialysis business, has been managed as a separate company following Fresenius’ deconsolidation of its controlling interest.

Fresenius SE & Co. KGaA is managed by Chief Executive Officer Michael Sen. The company is headquartered in Bad Homburg vor der Höhe, Germany.

View Fresenius SE & Co. Profile